Publications

2021

Cacciapuoti MT, Cappelli LV, Fiore D, Toruno P, Kayembe C, Tam W, et al. In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. Curr Protoc. 2021;1(4):e96.
Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Winger BA, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021;11(6):1424-1439.
DeSimone RA, Costa VA, Kane K, Sepulveda JL, Ellsworth GB, Gulick RM, et al. Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. Transfusion. 2021;61(3):692-698.
Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34(3):108638.
Moon CS, Reglero C, Cortes JR, S Quinn A, Alvarez S, Zhao J, et al. induces NF-κB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98-113.
O'Brien DA, Kaye SM, Poppas PJ, Mahase SS, An A, Christos PJ, et al. Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis. J Neurosurg. 2021:1-11.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, et al. Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. J Clin Endocrinol Metab. 2021;106(5):e2025-e2034.
Westblade LF, Magleby R, Trzebucki A, Simon MS, Rajan M, Park J, et al. Reply to Rhoads, et al. Clin Infect Dis. 2021;72(10):e687.
Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021;138(3):213-220.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700